Javier Pinilla-Ibarz, MD
Hematology · Tampa, FLNPI 1487736856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $988,084 of the $1,556,533 with a category attached, or 63.5%. 34 manufacturers reported payments, led by AstraZeneca at 25.4% of the total. Reporting peaked in 2019 at $355,488 and has fallen 52.9% since, to $167,424 in 2025. Among hematology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,013 payments — averaging $1536.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$395K
- AbbVie$223K
- Takeda Pharmaceuticals U.S.A., Inc.$156K
- Lilly USA, LLC$134K
- Johnson & Johnson$130K
- Beigene USA, Inc.$121K
- plus $397K from 28 others
Across 388 payments — averaging $6613.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- TG Therapeutics, Inc.$599K
- Acerta Pharma LLC$598K
- Incyte Corporation$509K
- Gilead$409K
- Novartis$286K
- F. Hoffmann-la Roche AG$148K
- plus $17K from 2 others
What the payments were for
- Consulting fees$390,19925%
- Speaking & faculty fees$988,08463%
- Travel & lodging$152,08510%
- Food & beverage$25,9732%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 255 | $394,832 |
| AbbVie | 151 | $223,419 |
| Takeda Pharmaceuticals U.S.A., Inc. | 86 | $155,609 |
| Lilly USA, LLC | 73 | $134,190 |
| Johnson & Johnson(2 entities) | 102 | $129,700 |
| Beigene USA, Inc. | 72 | $121,471 |
| Pharmacyclics LLC, An Abbvie Company | 67 | $85,273 |
| Sanofi | 31 | $62,308 |
| Janssen Global Services, LLC | 25 | $36,854 |
| Genentech USA, Inc. | 17 | $28,969 |
| Adaptive Biotechnologies Corporation | 17 | $27,689 |
| Secura Bio, Inc. | 23 | $24,393 |
| Novartis | 13 | $23,782 |
| Beone Medicines USA, Inc. | 17 | $22,993 |
| Teva Pharmaceuticals USA, Inc. | 8 | $18,394 |
| Pfizer(2 entities) | 7 | $16,229 |
| Eli Lilly | 6 | $11,753 |
| E.r. Squibb & Sons, L.L.C. | 7 | $10,967 |
| Astrazeneca UK Limited | 5 | $9,420 |
| TG Therapeutics, Inc. | 2 | $4,156 |
| Gilead(2 entities) | 4 | $2,513 |
| Genentech, Inc. | 1 | $2,310 |
| Cycle Pharmaceuticals Inc | 2 | $2,014 |
| Merck | 1 | $1,830 |
| Innate Pharma, Inc | 1 | $1,800 |
| Janssen Scientific Affairs, LLC | 3 | $1,725 |
| Amgen | 2 | $674 |
| Genmab U.S., Inc. | 5 | $498 |
| Morphosys, US Inc. | 4 | $212 |
| Stemline Therapeutics Inc. | 2 | $166 |
| Sanofi-aventis U.S. LLC | 1 | $141 |
| Bristol Myers Squibb | 1 | $131 |
| ADC Therapeutics America, Inc. | 1 | $95 |
| Seagen Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,556,533 in reported general payments places this provider in the 95th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 50 | $737,186 |
| ImbruvicaIbrutinib | 45 | $600,312 |
| BrukinsaZanubrutinib | 36 | $543,657 |
| VenclextaVenetoclax | 24 | $361,207 |
| JaypircaPirtobrutinib | 16 | $324,406 |
| BosulifBosutinib | 16 | $243,145 |
| SprycelDasatinib | 15 | $185,723 |
| Imatinib Mesylate | 27 | $165,018 |
| Acyclovir | 20 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $394,832 | $737,18650 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $85,273 | $600,31245 claims |
| Beigene USA, Inc.Brukinsa | $121,471 | $543,65736 claims |
| AbbVieVenclexta | $223,419 | $361,20724 claims |
| Lilly USA, LLCJaypirca | $134,190 | $324,40616 claims |
| PfizerBosulif | $16,229 | $243,14516 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $10,967 | $185,72315 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $18,394 | $18120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 hematology providers in Florida.
Other hematology in Tampa
- Rami KomrokjiTampa$855K
- Doris HansenTampa$141K
- Melissa AlsinaTampa$64K
- Alan ListTampa$49K
- Michael JainTampa$48K
- Lubomir SokolTampa$19K
- Kamran DarabiTampa$6K
- Lia PerezTampa$3K
- Nima GhalehsariTampa$3K
- Elizabeth SagatysTampa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.